Detalle Publicación


Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma

Autores: Garcés Latre, Juan José; Cedena, M. T.; Puig, N.; Burgos Rodríguez, Leire; Pérez, J. J.; Cordón, L. ; Flores-Montero, J.; Sanoja-Flores, L.; Calasanz Abinzano, María José; Ortiol, A.; Blanchard, M. J.; Ríos, R.; Martín, J.; Martínez-Martínez, R.; Bargay, J.; Sureda, A.; de la Rubia, J.; Hernández, M. T.; Rodríguez Otero, Paula; de la Cruz, J.; Orfao, A.; Mateos, M.- V.; Martínez-López, J.; Lahuerta, J. J.; Rosiñol, L.; Blade, J.; San Miguel Izquierdo, Jesús; Paiva, Bruno (Autor de correspondencia)
ISSN: 0732-183X
Volumen: 40
Número: 27
Páginas: 3151 - 3161
Fecha de publicación: 2022
PURPOSE Patients with multiple myeloma (MM) may show patchy bone marrow (BM) infiltration and extramedullary disease. Notwithstanding, quantification of plasma cells (PCs) continues to be performed in BM since the clinical translation of circulating tumor cells (CTCs) remains undefined. PATIENTS AND METHODS CTCs were measured in peripheral blood (PB) of 374 patients with newly diagnosed MM enrolled in the GEM2012MENOS65 and GEM2014MAIN trials. Treatment included bortezomib, lenalidomide, and dexamethasone induction followed by autologous transplant, consolidation, and maintenance. Next-generation flow cytometry was used to evaluate CTCs in PB at diagnosis and measurable residual disease (MRD) in BM throughout treatment. RESULTS CTCs were detected in 92% (344 of 374) of patients with newly diagnosed MM. The correlation between the percentages of CTCs and BM PCs was modest. Increasing logarithmic percentages of CTCs were associated with inferior progression-free survival (PFS). A cutoff of 0.01% CTCs showed an independent prognostic value (hazard ratio: 2.02; 95% CI, 1.3 to 3.1; P = .001) in multivariable PFS analysis including the International Staging System, lactate dehydrogenase levels, and cytogenetics. The combination of the four prognostic factors significantly improved risk stratification. Outcomes according to the percentage of CTCs and depth of response to treatment showed that patients with undetectable CTCs had exceptional PFS regardless of complete remission and MRD status. In all other cases with detectable CTCs, only achieving MRD negativity (and not complete remission) demonstrated a statistically significant increase in PFS. CONCLUSION Evaluation of CTCs in PB outperformed quantification of BM PCs. The detection of >= 0.01% CTCs could be a new risk factor in novel staging systems for patients with transplant-eligible MM.